Treatment and prevention of mania in bipolar I disorder: Focus on aripiprazole

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 279-288

  Muzina, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aripiprazole; Bipolar disorder; Mania; Prevention; Rapid cycling

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUVOXAMINE; GLUCOSE; HALOPERIDOL; KETOCONAZOLE; LAMOTRIGINE; LIPID; LITHIUM SALT; LORAZEPAM; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AGITATION; AKATHISIA; BEHAVIOR DISORDER; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DISEASE CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; INSOMNIA; LIPID BLOOD LEVEL; MAINTENANCE THERAPY; MANIA; MONOTHERAPY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NOTE; PHARYNGITIS; PROLACTIN BLOOD LEVEL; RECURRENT DISEASE; RELAPSE; REMISSION; RESTLESSNESS; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; THINKING; TREATMENT DURATION; TREMOR; VAGINITIS; WEIGHT GAIN; XEROSTOMIA;

EID: 70449716058     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s3763     Document Type: Note

References (45)

1. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol. 2008;11:999-1029.
2. Gerner RH, Post RM, Bunney WE Jr. A dopaminergic mechanism in mania. Am J Psychiatry. 1976;133:1177-1180.
3. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10:317-336. (Pubitemid 40128915)
4. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004:26:649-666. (Pubitemid 38736956)
5. Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 2005;5:297-307.
6. Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12:655-662. (Pubitemid 36512009)
7. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur J Pharmacol. 2008;597:27-33.
8. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60:974-977. (Pubitemid 37222078)
9. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006;31:1854-1863. (Pubitemid 44246331)
10. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004;18:375-383. (Pubitemid 39382565)
11. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93. (Pubitemid 40500867)
12. Garcia-Amador M, Pacchiarotti I, Valenti M, Sanchez RF, Goikolea JM, Vieta E. Role of aripiprazole in treating mood disorders. Expert Rev Neurother. 2006;6:1777-1783. (Pubitemid 46023428)
13. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658. (Pubitemid 41079552)
14. Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68:1480-1491.
15. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20:536-546. (Pubitemid 43875183)
16. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry. 2007;68:1377-1383. (Pubitemid 47524517)
17. Frye MA, Eudicone J, Pikalov A, McQuade RD, Marcus RN, Carlson BX. Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials. J Clin Psychopharmacol. 2008;28:243-245.
18. Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008;107:145-154. (Pubitemid 351288925)
19. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187:235-242. (Pubitemid 41306104)
20. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009;112:36-49.
21. Vieta E, T'Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008;165:1316-1325.
22. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626-637. (Pubitemid 43764240)
23. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007;27:171-176. (Pubitemid 46594934)
24. Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract. 2008;62:679-687.
25. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry. 2005;39:652-661. (Pubitemid 43904367)
26. Ghaemi SN, Hsu DJ, Rosenquist KJ, Pardo TB, Goodwin FK. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:209-213. (Pubitemid 43288060)
27. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28:203-209.
28. American Diabetes Association (ADA). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
29. Lim HK, Pae CU, Lee C, Lee CU. Tardive dystonic symptoms associated with aripiprazole treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:589-590. (Pubitemid 351178977)
30. Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr. 2006;11:435-439.
31. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004;19:351-353.
32. Shim JC, You YS, Kelly DL. Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report. J Clin Psychopharmacol. 2008;28:353-354.
33. Sheldrick AJ, Grunder G. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis. Pharmacopsychiatry. 2008;41:160.
34. Malik AR, Ravasia S. Aripiprazole-induced seizure. Can J Psychiatry. 2005;50:186.
35. Tsai JF. Aripiprazole-associated seizure. J Clin Psychiatry. 2006;67:995-996.
36. Ghaemi SN, Stoll AL, Pope HG Jr. Lack of insight in bipolar disorder. The acute manic episode. J Nerv Ment Dis. 1995;183:464-467.
37. Varga M, Magnusson A, Flekkoy K, Ronneberg U, Opjordsmoen S. Insight, symptoms and neurocognition in bipolar I patients. J Affect Disord. 2006;91:1-9. (Pubitemid 43254631)
38. Ghaemi SN, Boiman E, Goodwin FK. Insight and outcome in bipolar, unipolar, and anxiety disorders. Compr Psychiatry. 2000;41:167-171. (Pubitemid 30322481)
39. Yen CF, Chen CS, Yeh ML, Yang SJ, Ke JH, Yen JY. Changes of insight in manic episodes and influencing factors. Compr Psychiatry. 2003;44:404-408.
40. Yen CF, Chen CS, Yen JY, Ko CH. The predictive effect of insight on adverse clinical outcomes in bipolar I disorder: a two-year prospective study. J Affect Disord. 2008a; 108:121-127.
41. Yen CF, Cheng CP, Huang CF, Yen JY, Ko CH, Chen CS. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission. Bipolar Disord. 2008b; 10:617-624.
42. Yen CF, Cheng CP, Ko CH, Yen JY, Huang CF, Chen CS. Suicidality and its association with insight and neurocognition in taiwanese patients with bipolar I disorder in remission. J Nerv Ment Dis. 2008c:196:462-467.
43. Sajatovic M, Jenkins JH. Is antipsychotic medication stigmatizing for people with mental illness? Int Rev Psychiatry. 2007;19:107-112. (Pubitemid 46676524)
44. Copeland LA, Zeber JE, Salloum IM, Pincus HA, Fine MJ, Kilbourne AM. Treatment adherence and illness insight in veterans with bipolar disorder. J Nerv Ment Dis. 2008;196:16-21.
45. Fagiolini A. Practical guidance for prescribing with aripiprazole in bipolar disorder. Curr Med Res Opin. 2008;24:2691-2702.